The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

There were no serious adverse events or treatment-related mortalities. Evidence Rating Level: 2 (Good) Study Rundown: Transfusion-dependent β-thalassemia (TDT) is a condition that results in iron ...

Thomas J. Klima, the Chief Commercial and Operating Officer of bluebird bio, Inc. (NASDAQ:BLUE), recently sold shares of the company’s common stock. According to a recent SEC filing, Klima disposed of ...

In a recent transaction, Richard A. Colvin, the Chief Medical (TASE:PMCN) Officer of bluebird bio, Inc. (NASDAQ:BLUE), sold shares of the company's common stock. On February 3, 2025, Colvin sold 64 ...

Thirty patients have received the gene therapy within a clinical trial and early-access program, and the foundation also hopes to seek approval in the US.

Oxford, UK - 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the ...

Telethon Foundation is seeking approval for a gene therapy to treat the rare disease Wiskott-Aldrich syndrome.